These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10030167)

  • 21. Therapy of HIV infection.
    Chang YC; Tyring SK
    Dermatol Ther; 2004; 17(6):449-64. PubMed ID: 15571495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current clinical treatments of AIDS.
    Murphy EM; Jimenez HR; Smith SM
    Adv Pharmacol; 2008; 56():27-73. PubMed ID: 18086408
    [No Abstract]   [Full Text] [Related]  

  • 23. ICAAC and Hamburg: Part 1. Schmuddelwetter or, rating protease inhibitors on the pass/fail system.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1997 Dec; 3(12):29-37. PubMed ID: 11364943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological considerations in antiretroviral therapy.
    Sommadossi JP
    Antivir Ther; 1998; 3 Suppl 4():9-12. PubMed ID: 10723503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can responses to antiretroviral therapy be improved by therapeutic drug monitoring?
    Haas DW
    Clin Infect Dis; 2006 Apr; 42(8):1197-9. PubMed ID: 16575742
    [No Abstract]   [Full Text] [Related]  

  • 26. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 27. Nonnucleoside reverse transcriptase inhibitors.
    Murphy RL
    AIDS Clin Care; 1997 Oct; 9(10):75-7, 79. PubMed ID: 11364757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New antiretroviral tactics: transitions or mere trends? An interview with Joep Lange,MD,PhD. Interview by Mark Mascolini.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1999 Jul; 5(7):25-9. PubMed ID: 11367133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing issues related to antiretroviral therapy.
    Lesho EP; Gey DC
    Am Fam Physician; 2003 Aug; 68(4):675-86. PubMed ID: 12952384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.
    Persaud D; Palumbo P; Ziemniak C; Chen J; Ray SC; Hughes M; Havens P; Purswani M; Gaur AH; Chadwick EG;
    J Infect Dis; 2007 May; 195(10):1402-10. PubMed ID: 17436219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV resistance: the new enemy.
    Colvin R
    Common Factor; 1997 Nov; (No 11):6-7. PubMed ID: 11364845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
    Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
    J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection.
    Gerber JG
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S123-9. PubMed ID: 10860896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daily dosing of highly active antiretroviral therapy.
    Rosenbach KA; Allison R; Nadler JP
    Clin Infect Dis; 2002 Mar; 34(5):686-92. PubMed ID: 11823957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New antiretroviral agents].
    Roca B; Simón E
    An Med Interna; 1998 Nov; 15(11):606-14. PubMed ID: 9882861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiretroviral therapy 2010 update: current practices and controversies.
    Grant M; Samuel R; Bettiker RL; Suh B
    Arch Pharm Res; 2011 Jul; 34(7):1045-53. PubMed ID: 21811910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New era in AIDS therapy with highly active anti-retroviral agents].
    Maayan S
    Harefuah; 1998 Feb; 134(3):190-3. PubMed ID: 9662910
    [No Abstract]   [Full Text] [Related]  

  • 39. Recent advances in antiretroviral drugs.
    Ghosh RK; Ghosh SM; Chawla S
    Expert Opin Pharmacother; 2011 Jan; 12(1):31-46. PubMed ID: 20698725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expanded access to experimental drugs: activists seek more open programs.
    Grinberg L
    AIDS Treat News; 1997 Nov; (No 282):6-7. PubMed ID: 11364904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.